Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Accolade 12.3

13 Jun 2019 07:00

RNS Number : 0247C
Sopheon PLC
13 June 2019
 

SOPHEON PLC

("Sopheon" or the "Company")

 

New Sopheon Release Enhances Corporate Adaptability

 

Accolade® 12.3 enables local flexibility to react quickly to markets, eases risk management, and frees up teams for high-value contributions.

 

Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, today releases the latest version of its Accolade® Enterprise Innovation Management solution, extending the corporate adaptability strategy introduced in Accolade 12.2.

 

While digital and business transformation are top corporate priorities, it is widely recognized that most corporations are unable to respond quickly to external conditions or move fast enough to be the market disruptor and not the disrupted. They lack an operating model that simultaneously offers both connectivity and flexibility. Operational business units, segments and regional entities need the freedom to respond to their markets while remaining aligned with the corporate strategy and key performance indicators. Along with this, employees need to be freed from menial administrative tasks to focus on higher-value contributions that move the dial. Sopheon calls this capability "corporate adaptability."

 

 "Corporations will not survive in the digital age unless they adopt a new digital operating model that allows them to move faster than their outside markets while operating within corporate strategic guidelines and governance," said Andy Michuda, Sopheon CEO. "Accolade 12.3 has been created in partnership with a number of clients who are some of the most progressive, world-leading companies, in an effort to enable traditional market leaders to compete and win in today's fast-paced economy."

 

Accolade 12.3 introduces new capabilities aimed at solving for this challenge including features that offer:

 

· More localized flexibility without compromise to corporate governance

· Transparency of dependencies and notifications for risk management

· Enhanced user experience and time savings through smart automation

 

Tristen Branson, Product Innovation Manager at Australian Paper, added: "We are very pleased with Accolade 12.3 advances in user friendliness that will save our users time in their work, while providing management the information they need for better decision making."

 

For further information contact:

Barry Mence (Chairman)Arif Karimjee (CFO)

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes/Giles Rolls (Corporate Finance)Alice Lane (ECM)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 250 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRALLFLRRRIFLIA
Date   Source Headline
30th Jan 201810:27 amRNSIssue of Equity
29th Jan 20187:00 amRNSTrading Update
4th Jan 20182:05 pmRNSSecond Price Monitoring Extn
4th Jan 20182:00 pmRNSPrice Monitoring Extension
4th Jan 20187:00 amRNSTrading Update
22nd Dec 20171:01 pmRNSHolding(s) in Company
22nd Dec 201712:37 pmRNSConversion of Loan Stock
8th Dec 20177:00 amRNSAmendment to the Terms of Convertible Loan Stock
9th Nov 20177:00 amRNSCertis Europe Partners with Sopheon
19th Oct 20177:00 amRNSSopheon Funding Award
11th Oct 201710:44 amRNSDirector/PDMR Shareholding
2nd Oct 20177:00 amRNSIssue of Equity
26th Sep 20177:00 amRNSSopheon "Leader" in Strategic Portfolio Management
5th Sep 20177:00 amRNSSopheon's Accolade Software beyond innovation
24th Aug 20177:00 amRNSHalf Yearly Report
21st Jul 201710:32 amRNSDirector Shareholdings
6th Jul 20177:00 amRNSAccolade Release 11.2
29th Jun 20177:00 amRNSNew Approach to Product Development with Accolade
13th Jun 201712:04 pmRNSDirector Shareholdings
8th Jun 201712:09 pmRNSResult of AGM
8th Jun 20177:00 amRNSAGM Statement
26th May 20174:33 pmRNSIssue of Equity
26th Apr 20173:50 pmRNSIssue of Equity
12th Apr 201712:01 pmRNSIssue of Equity
7th Apr 20171:37 pmRNSDirector Shareholdings
31st Mar 20177:00 amRNSDirector Shareholdings
31st Mar 20177:00 amRNSIssue of Equity
23rd Mar 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSAccolade Release 11.1
16th Feb 20177:00 amRNSGrant of Options / PDMR dealing
30th Jan 20177:00 amRNSTrading Update
21st Nov 201611:50 amRNSIssue of Equity
3rd Nov 20168:00 amRNSAccolade Release 11.0
29th Sep 201612:41 pmRNSIssue of Equity
22nd Sep 20169:09 amRNSIssue of Equity
15th Sep 20163:09 pmRNSIssue of Equity
25th Aug 20167:00 amRNSHalf Yearly Report
28th Jul 20165:01 pmRNSHolding(s) in Company
26th Jul 201610:49 amRNSHolding(s) in Company
12th Jul 201610:48 amRNSHolding(s) in Company
29th Jun 20165:32 pmRNSDirector Dealing
16th Jun 20164:22 pmRNSDirector Dealing
14th Jun 20164:18 pmRNSDirector Dealing
10th Jun 20162:13 pmRNSDirector Dealing
9th Jun 201611:37 amRNSResult of AGM
9th Jun 20167:00 amRNSAGM Statement
31st May 20163:09 pmRNSIssue of Equity
5th May 20161:25 pmRNSHolding(s) in Company
4th May 20167:00 amRNSAccolade Release 10.3
3rd May 20161:27 pmRNSDirector Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.